Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022)

4D Molecular Therapeutics (FDMT) has disclosed Change in Receivables for 3 consecutive years, with -$47000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Change in Receivables rose 90.98% to -$47000.0 in Q1 2022 year-over-year; TTM through Dec 2022 was -$47000.0, a 96.73% increase, with the full-year FY2022 number at -$47000.0, up 96.73% from a year prior.
  • Change in Receivables was -$47000.0 for Q1 2022 at 4D Molecular Therapeutics, up from -$744000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $590000.0 in Q4 2020 to a low of -$744000.0 in Q4 2021.
  • A 3-year average of -$108666.7 and a median of -$99000.0 in 2020 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 267.55% in 2021; the steepest drop was 426.26% in 2021.
  • 4D Molecular Therapeutics' Change in Receivables stood at $590000.0 in 2020, then crashed by 226.1% to -$744000.0 in 2021, then surged by 93.68% to -$47000.0 in 2022.
  • Per Business Quant, the three most recent readings for FDMT's Change in Receivables are -$47000.0 (Q1 2022), -$744000.0 (Q4 2021), and -$427000.0 (Q3 2021).